ストックスクリーナーアプリを入手
43.57
0.11%
0.0134
前日終値:
$43.56
開ける：
$43.76
24時間の取引高:
140.73K
Relative Volume:
0.20
時価総額：
$1.98B
収益：
$1.23B
当期純損益:
$20.43M
株価収益率:
98.78
EPS:
0.4411
ネットキャッシュフロー:
$95.39M
1週間 パフォーマンス:
+1.18%
1か月 パフォーマンス:
+27.85%
6か月 パフォーマンス:
+21.95%
1年 パフォーマンス:
+69.95%
1日の値動き範囲:
$43.04
$44.15
1週間の範囲:
$41.12
$44.45
52週間の値動き範囲:
$24.23
$55.00
Omnicell Inc Stock (OMCL) Company Profile
Compare OMCL vs VEEV, BTSG, TEM, HQY, DOCS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OMCL
Omnicell Inc
|
43.61 | 1.98B | 1.23B | 20.43M | 95.39M | 0.4411 |
VEEV
Veeva Systems Inc
|
169.21 | 27.94B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
52.34 | 9.98B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
51.12 | 9.70B | 1.27B | -245.03M | -245.36M | -1.4071 |
HQY
Healthequity Inc
|
83.00 | 6.98B | 1.31B | 215.20M | 408.32M | 2.4627 |
DOCS
Doximity Inc
|
25.56 | 4.76B | 637.78M | 239.40M | 307.21M | 1.1909 |
Omnicell Inc Stock (OMCL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-04 | アップグレード | BofA Securities | Neutral → Buy |
| 2026-01-08 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-05-14 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-10-31 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-08-02 | アップグレード | Barclays | Underweight → Equal Weight |
| 2024-01-03 | 開始されました | Barclays | Underweight |
| 2023-11-03 | ダウングレード | BTIG Research | Buy → Neutral |
| 2023-11-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-11-03 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2023-10-11 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-09-26 | 繰り返されました | Wells Fargo | Underweight |
| 2023-08-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-07-20 | ダウングレード | Wells Fargo | Overweight → Underweight |
| 2023-02-27 | アップグレード | The Benchmark Company | Hold → Buy |
| 2022-11-03 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-09-09 | 開始されました | BofA Securities | Buy |
| 2022-07-15 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-12-06 | 再開されました | Wells Fargo | Overweight |
| 2021-06-09 | 開始されました | JP Morgan | Neutral |
| 2021-05-24 | 開始されました | BTIG Research | Buy |
| 2021-02-02 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-12-08 | 開始されました | Berenberg | Buy |
| 2020-12-03 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2020-07-07 | 開始されました | Stephens | Overweight |
| 2020-02-07 | 繰り返されました | Dougherty & Company | Buy |
| 2019-11-21 | 繰り返されました | Dougherty & Company | Buy |
| 2019-07-26 | アップグレード | Craig Hallum | Hold → Buy |
| 2019-03-07 | 繰り返されました | Dougherty & Company | Buy |
| 2018-06-29 | 再開されました | The Benchmark Company | Buy |
| 2017-09-05 | 繰り返されました | The Benchmark Company | Buy |
| 2017-07-28 | 繰り返されました | Dougherty & Company | Buy |
| 2017-04-21 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-01-19 | 開始されました | Dougherty & Company | Buy |
| 2016-12-06 | 繰り返されました | The Benchmark Company | Buy |
| 2016-07-07 | 繰り返されました | FBR Capital | Outperform |
| 2016-03-21 | 繰り返されました | Topeka Capital Markets | Buy |
| 2016-01-07 | 開始されました | The Benchmark Company | Buy |
| 2015-11-16 | 繰り返されました | Topeka Capital Markets | Buy |
| 2015-10-30 | 繰り返されました | FBR Capital | Outperform |
| 2015-09-28 | アップグレード | Sidoti | Neutral → Buy |
| 2015-07-31 | 繰り返されました | Topeka Capital Markets | Buy |
すべてを表示
Omnicell Inc (OMCL) 最新ニュース
Wall Street analysts see a 41.19% upside in Omnicell (OMCL): Can the stock really move this high? - MSN
Omnicell lifts 2026 non-GAAP EPS outlook to $1.80-$2.00 as Titan XT shipments are planned for 2H 2026 - MSN
Omnicell (OMCL) Is Up 13.7% After Earnings Beat, Raised Guidance, And Key Pharmacy HireWhat's Changed - Sahm
Omnicell (OMCL) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
North America Central Fill Pharmacy Automation Market Growth - openPR.com
Zacks Industry Outlook Highlights Veeva Systems, Doximity and Omnicell - Yahoo Finance
Surging earnings estimates signal upside for Omnicell (OMCL) stock - MSN
The 5 Most Interesting Analyst Questions From Omnicell’s Q1 Earnings Call - TradingView
Omnicell to Present at the BofA Securities 2026 Healthcare Conference - BioSpace
Omnicell gets relative strength rating upgrade - MSN
Omnicell's May 12 healthcare conference presentation will stream live - Stock Titan
Surging Earnings Estimates Signal Upside for Omnicell (OMCL) Stock - Yahoo Finance
Wall Street Analysts See a 41.19% Upside in Omnicell (OMCL): Can the Stock Really Move This High? - Yahoo Finance
Discipline and Rules-Based Execution in OMCL Response - Stock Traders Daily
Assessing Omnicell (OMCL) Valuation After Q1 Earnings Beat And Higher EPS Guidance - Yahoo Finance
Omnicell (OMCL) Q1 2026 Earnings Transcript - AOL.com
Omnicell Stock Soars 20.94%, Hits Intraday High of $46.85 - Markets Mojo
Omnicell (NASDAQ:OMCL) Raised to Buy at Wall Street Zen - MarketBeat
Omnicell OMCL Q2 2025 Earnings Transcript - AOL.com
A Look at Omnicell Inc (OMCL) After 3.3% Gain -- GF Value $38.55 vs Price $42.80 - GuruFocus
Omnicell (OMCL) Q1 2025 Earnings Transcript - AOL.com
Here's why Omnicell (OMCL) is a strong value stock - MSN
Omnicell Q1 Earnings & Revenues Top, Stock Up, Gross Margin Rises - Yahoo! Finance Canada
Vanguard holds 2.27M shares in Omnicell (NASDAQ: OMCL) - Stock Titan
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Rocket Pharmaceuticals (RCKT) and Cullinan Management (CGEM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL) and Shattuck Labs (STTK) - The Globe and Mail
Omnicell Reports Strong Q1 2026 Earnings, Raises Full-Year GuidanceNews and Statistics - IndexBox
Omnicell (OMCL) Q1 EPS Recovery Tests Bullish Margin Improvement Narrative - simplywall.st
Omnicell Earnings Call Shows Profits Surging, Outlook Raised - The Globe and Mail
Omnicell (NASDAQ:OMCL) Shares Down 7.4%Here's Why - MarketBeat
Vanguard (NASDAQ: OMCL) owns 3.24M Omnicell shares, 7.13% stake - Stock Titan
Omnicell appoints Rick Couldry as SVP, chief pharmacy and clinical officer - TipRanks
Omnicell welcomes hospital pharmacy leader Rick Couldry as senior vice president - marketscreener.com
Analyst Reiterates Buy on Omnicell, Citing Once-in-a-Decade Product Cycle Momentum and Margin Strength; Price Target Maintained at $70 - TipRanks
Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer - BioSpace
Omnicell names Rick Couldry as senior vice president, chief pharmacy and clinical officer - Fort Worth Report
Investment Advisor Sells $6.6 Million Worth of Medical Solutions Stock, According to Recent SEC Filing - The Globe and Mail
OMCL Maintained by Keybanc -- Price Target Raised to $70 - GuruFocus
Omnicell Names Rick Couldry Chief Pharmacy and Clinical Officer - Fort Worth Inc.
KeyBanc raises Omnicell stock price target to $70 on growth outlook By Investing.com - Investing.com South Africa
KeyBanc raises Omnicell stock price target to $70 on growth outlook - Investing.com Australia
Omnicell, Inc. (NASDAQ:OMCL) Q1 2026 Earnings Call Transcript - Insider Monkey
Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry As Senior Vice President - TradingView
Omnicell Q1 2026 earnings preview - MSN
TX-OMNICELL-INC. - Black Hills Pioneer
Omnicell, Inc. Appoints Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer - marketscreener.com
OMCL Q1 Deep Dive: Platform Expansion and Cost Controls Drive Margin Turnaround - StockStory
Omnicell Inc (OMCL) Q1 2026 Earnings Call Highlights: Strong Rev - GuruFocus
Omnicell Welcomes Hospital Pharmacy Leader Rick Couldry as Senio - GuruFocus
Omnicell to Release First Quarter 2026 Financial Results on April 28, 2026 - Quantisnow
Omnicell Q1 Non-GAAP Earnings, Revenue Rise; 2026 Non-GAAP Earnings Outlook Lifted - Moomoo
Omnicell Inc (OMCL) 財務データ
収益
当期純利益
現金流量
EPS
2.18%
2.11%
大文字化:
|
ボリューム (24 時間):